PMID- 24798307
OWN - NLM
STAT- MEDLINE
DCOM- 20141218
LR  - 20191210
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 98
IP  - 5
DP  - 2014 Sep 15
TI  - Who is the best hematopoietic stem-cell donor for a male patient with acute 
      leukemia?
PG  - 569-77
LID - 10.1097/TP.0000000000000102 [doi]
AB  - BACKGROUND: Female donors for male recipients worsen the outcome of allogeneic 
      hematopoietic stem-cell transplantation. We wanted to find out whether a male 
      human leukocyte antigen (HLA)-matched unrelated donor (MUD, 8/8, n=2,014) might 
      be an alternative to a female HLA-identical sibling donor (n=2,656) for male 
      patients with acute leukemia. METHODS: This is a retrospective analysis from the 
      Acute Leukaemia Working Party of the European Group for Blood and Marrow 
      Transplantation. RESULTS: The relative risk (RR) of acute graft-versus-host 
      disease (GVHD) of grades II to IV was increased in the MUD group with acute 
      myeloid leukemia (AML) (RR, 1.47; P<0.001) and acute lymphoblastic leukemia (ALL) 
      (RR, 1.76; P<0.001). There was no difference in incidence of chronic GVHD and 
      nonrelapse mortality between the two groups. Probability of relapse was lower in 
      the MUD group than in the sibling group in patients with ALL (hazards ratio [HR], 
      0.75; P=0.04) but not in the AML patients (HR, 0.89; P=0.17). Survival was not 
      different between the groups. Leukemia-free survival (LFS) was also similar in 
      the sibling and MUD groups in patients with AML (HR, 1.01; P=0.81) or ALL (HR, 
      0.93; P=0.45). Factors significantly associated with reduced LFS included active 
      disease, poor cytogenetics, age, year of hematopoietic stem-cell transplantation, 
      reduced-intensity conditioning, and the use of antithymocyte globulin. 
      CONCLUSION: Male patients who received grafts from male MUDs demonstrated an 
      increased incidence of acute GVHD and LFS same as when using HLA-identical female 
      donors.
FAU - Ringden, Olle
AU  - Ringden O
AD  - 1 Center for Allogeneic Stem Cell Transplantation and Division of Therapeutic 
      Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, 
      Stockholm, Sweden. 2 Department of Haematology, Hopital Saint Antoine, Paris, 
      France. 3 Department of Bone Marrow Transplantation, Essen, University Hospital, 
      Essen, Germany. 4 Medizinische Klinik m. S. Hamatologie/Onkologie, Charite 
      Universitatsmedizin, Berlin, Germany. 5 Medizinische Klinik und Poliklinik I, 
      Universitatsklinikum Dresden, Dresden, Germany. 6 CHU Bordeaux, Hopital 
      Haut-leveque, Pessac, France. 7 Division of Hematology, Oncology and 
      Hemostasiology, University Hospital Leipzig, Leipzig, Germany. 8 Service 
      Hematologie Greffe de Moelle, Centre Pierre et Marie Curie, Alger, Algeria. 9 
      Department of Hematology and BMT, Silesian Medical Academy, Katowice, Poland. 10 
      Department of Hematology/Oncology, Hannover Medical University, Hannover, 
      Germany. 11 Department of Hematology - BMT, Hopital St. Louis, Paris, France. 12 
      Department of Hematology/Oncology, University of Munster, Munster, Germany. 13 
      Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland. 
      14 Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United 
      Kingdom. 15 Address correspondence to: Olle Ringden, M.D., Ph.D., Karolinska 
      Institutet, Division of Therapeutic Immunology, Karolinska University Hospital 
      Huddinge, F79, SE-141 86 Stockholm, Sweden.
FAU - Labopin, Myriam
AU  - Labopin M
FAU - Solders, Martin
AU  - Solders M
FAU - Beelen, Dietrich
AU  - Beelen D
FAU - Arnold, Renate
AU  - Arnold R
FAU - Ehninger, Gerhard
AU  - Ehninger G
FAU - Milpied, Noel
AU  - Milpied N
FAU - Niederwieser, Dietger
AU  - Niederwieser D
FAU - Hamladji, Rose-Marie
AU  - Hamladji RM
FAU - Kyrcz-Krzemien, Slawomira
AU  - Kyrcz-Krzemien S
FAU - Ganser, Arnold
AU  - Ganser A
FAU - Socie, Gerard
AU  - Socie G
FAU - Stelljes, Matthias
AU  - Stelljes M
FAU - Volin, Liisa
AU  - Volin L
FAU - Craddock, Charles
AU  - Craddock C
FAU - Mohty, Mohamad
AU  - Mohty M
CN  - Acute Leukaemia Working Party of the European Group for Blood and Marrow 
      Transplantation
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Graft vs Host Disease/epidemiology/etiology/*prevention & control
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Incidence
MH  - Leukemia, Myeloid, Acute/immunology/mortality/*therapy
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology/mortality/*therapy
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sex Factors
MH  - Survival Analysis
MH  - Transplantation, Homologous/methods
MH  - Treatment Outcome
MH  - *Unrelated Donors
MH  - Young Adult
EDAT- 2014/05/07 06:00
MHDA- 2014/12/19 06:00
CRDT- 2014/05/07 06:00
PHST- 2014/05/07 06:00 [entrez]
PHST- 2014/05/07 06:00 [pubmed]
PHST- 2014/12/19 06:00 [medline]
AID - 10.1097/TP.0000000000000102 [doi]
PST - ppublish
SO  - Transplantation. 2014 Sep 15;98(5):569-77. doi: 10.1097/TP.0000000000000102.